Completed PHASE1 INTERVENTIONAL 1-arm NCT03163173

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

Sponsor: Celerion

Interventions GC4419

Updated 6 times since 2017 Last updated: Nov 15, 2017 Started: Aug 14, 2017 Primary completion: Oct 13, 2017 Completion: Oct 13, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and Healthy Volunteers and is currently completed. Celerion leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Dec 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed

▶ Show 1 earlier version

Jul 2017 — Dec 2017 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celerion
Galera Therapeutics, Inc.

Data source: Galera Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lincoln, United States